Wealth Enhancement Advisory Services
LRMR icon

Wealth Enhancement Advisory Services’s Larimar Therapeutics LRMR Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Buy
63,680
+30,881
+94% +$123K ﹤0.01% 3292
2026
Q1 		$157K Buy
32,799
+17,185
+110% +$68.7K ﹤0.01% 3216
2025
Q4 		$52.6K Sell
15,614
-2,634
-14% -$10.2K ﹤0.01% 3531
2025
Q3 		$86.1K Buy
18,248
+4,619
+34% +$17.3K ﹤0.01% 3358
2025
Q2 		$43.6K Buy
+13,629
New +$31.6K ﹤0.01% 3242

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Wealth Enhancement Advisory Services's LRMR Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Larimar Therapeutics (LRMR) stake by 94% in Q2 2026, buying an estimated $123K and bringing the position to 63,680 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #3292.

Wealth Enhancement Advisory Services first reported a position in LRMR in Q2 2025 and has held it in 5 quarters since. 162 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Wealth Enhancement Advisory Services held 63,680 shares of Larimar Therapeutics worth $273K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 30,881 Larimar Therapeutics shares in Q2 2026, an estimated $123K.
  • Larimar Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3292 holding.
  • Wealth Enhancement Advisory Services first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.